卵巢上皮細胞癌(Epithelial Ovarian Cancer)血清中Mesothelin: 一個新的篩選標記和預後因子

Abstract

Objective. To investigate the relationship between serum mesothelin and clinico-pathological factors, and to determine whether mesothelin is a biomarker for detection and an independent prognostic factor of ovarian cancer. Methods. Twenty-four normal populations, 20 women with benign ovarian lesion, or 122 patients with epithelial ovarian cancer were enrolled. Clinical and pathologic items were recorded. Pretreatment mesothelin and CA125 serum samples of these women were measured by an enzyme-linked immunosorbent assay. The results were correlated to clinical data. The histopathologic items and serum meosthelin, and CA125 influencing clinical outcome were evaluated comparatively. Results. The preoperative serum levels of mesothelin (OD450 ratio) (2.465 vs. 1.384 vs. 0.912) were higher in ovarian cancer patients than in those with benign ovarian lesions or normal populations. The preoperative serum levels of mesothelin also significantly increased from stage I to IV. Elevated mesothelin serum levels before therapy (1.51 (1.02-2.24), Relative risk (95%CI)) and advanced stages (1.61 (1.03-2.49)) showed significantly poorer overall survival (OS) for 122 cancer patients. Elevated mesothelin serum levels before therapy also revealed significantly poorer OS for 83 cancer patients with optimal debulking surgery (1.59 (1.02-2.48)) and for 79 advanced-staged cancer patients (2.18 (1.09-4.38)). Conclusions. Pretreatment mesothelin serum levels might be regarded a new tumor marker for the differential diagnosis of ovarian cancer and an additional prognostic factor in predicting the outcome of ovarian carcinoma patients.